- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 1 15 minutes: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS 20 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Professor Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 2 12 minutes: PSMA-PET Diagnostic Imaging in Prostate Cancer - Presented by Thomas Hope, MD Module 3 16 minutes: PSMA as a Therapeutic Target in Progressing Prostate Cancer - Presented by Johannes Czernin, MD 22 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Joh...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 4 10 minutes: Treatment considerations following 177Lu-PSMA - Presented by Scott Tagawa, MD, MS, FACP 17 minutes: PSMA Imaging: A Necessary Gateway for PSMA-Directed Therapy? - Presented by Michael Morris, MD 24 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Sco...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer. Module 5 12 minutes: PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Presented by Oliver Sartor, MD 11 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Oliver Sartor, M.D. C.E. and Bernadine Laborde Professor of...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 6 14 minutes: Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Presented by Stefano Fanti, MD 15 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Stefano Fanti, MD Nuclear Medicine Physician, Director of the Nuclear Medicine Division and PET Uni...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 7 9 minutes: Academic Practice Perspectives on Integrating PSMA Lu-177 into Clinical Practice: Lessons Learned from Radium-223 and More - Presented by Oliver Sartor, MD. 6 minutes: Practice Patterns in a Community Medical Oncology Applied to Lutetium: Parallels between lutetium and operationalizing radium-223 - Presented by N...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer. Module 8 19 minutes: Radiation Safety with Targeted Radionuclide Therapy - Presented by Thomas Hope, MD 24 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the...
|
- Details
- Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study "A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy." Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localized prostate canc...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...
|
- Details
- Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative en...
|
